Issue Date: July 21, 2008
Lonza Snares Novartis Contract
Lonza has secured a long-term contract to help develop and manufacture biopharmaceuticals in Novartis' pipeline. Working out of its R&D center in Slough, England, the Swiss contract manufacturer will apply its gene expression system to Novartis drug candidates. Lonza will then make the drugs at sites in the U.S., Spain, and Singapore. The deal represents a shift from a typical contract arrangement to a more collaborative approach, and it gives Novartis extra capacity and technical support.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society